Abstract: TH-PO925
The Safety and Humoral Response to COVID-19 Vaccination in Peritoneal Dialysis Patients
Session Information
- COVID-19: Vaccines and Outcomes ESRD/KTR
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Chen, Cheng-Hsu, Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Taiwan
- Shih, Chia-Yu, Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Taiwan
Background
The battle between human and COVID-19 since 2019, it is highly contagious and fatal disease with poor outcome in dialysis patients. The viral vector AZD1222 is a replication deficient simian adenovirus-vectored vaccine encoding the full length SARS-CoV-2 spike protein. The efficacy and safety of AZD1222 in patients treated with peritoneal dialysis (PD) is still not knowing. We focused their seroresponse of nAb titers against SARS-CoV-2 and their local and systemic adverse effects.
Methods
We conducted this study to elucidate the immune response directed against SARS-CoV-2 spike (S) protein antigen and adverse effect to vaccination with AZD1222 in PD patients after their 1st and 2nd shots. There were 205 out of 263 PD patients received the first shot of AZD1222, and 192 of them had the second shot between June 2021 to Oct. 2021.
Results
The first and second doses of AZD1222 vaccine 13 (9.1%) and 93 (65.0%) of 143 PD patients seroconverted with anti-SARS-CoV-2 S antibody titers (≥ 50 U/mL), and titers presented with 188.54 U/mL (mean; IQR 54.7-739.6) and significantly increased to 1545.3 U/mL (mean ; IQR 52.0-38460), respectively. Pain was the most common local adverse event (AE) (75%). Systemic AEs occurring after the first dose were mostly fatigue (41%) and headache (31%). One severe AE were reported as hearing loss and stroke after the first injection. After the second dose, the most common systemic AEs were fatigue (40.5%), headache (22.5%), joint pain (20%), myalgia (17.5%) and fever (16%), but no severe AE reported. Patients with higher antibody titers after the first dose tended to have higher antibody titers after the second dose (p=1.23x10-4).
Conclusion
Our study concludes that significantly increasing humoral responses to AZD1222 vaccination in PD patients are from 9.1% after 1st shot and 65% after 2nd shot. While acceptable local and systemic adverse events, viral vector AZD1222 is still safe and effective vaccination for PD patients.